Clinical Trials Logo

Citation(s)

Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma

Details for clinical trial NCT00059995